X0508 4 2024-04-01 0001840574 Verve Therapeutics, Inc. VERV 0001964461 Nickerson Joan C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 false true false false Chief Administrative Officer true Common Stock 2024-04-01 4 M false 3315 A 10173 D Common Stock 2024-04-02 4 S false 1514 8.24 D 8659 D Restricted Stock Units 2024-04-01 4 M false 3315 0 D Common Stock 3315 9945 D Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date. Includes 1,364 shares of the Company's common stock acquired in 2023 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan. This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 17, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person. On February 14, 2023, the reporting person was granted 13,260 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2024 and the remainder vesting in equal annual installments until April 1, 2027. /s/ Andrew Ashe, as Attorney-in-Fact for Joan Nickerson 2024-04-03